Lenvatinib may decrease tumor-associated macrophages, facilitate polarization from an M2-like phenotype toward an M1-like phenotype, and enhance CD4+ and CD8+ T-cell tumor infiltration, while sorafenib may have the opposite effects [35]. The gene discussed is CD4; the disease is neoplasm.